

ZIOPHARM ONCOLOGY INC  
Form 8-K  
December 26, 2006

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
WASHINGTON, D.C. 20549

**FORM 8-K**

CURRENT REPORT  
PURSUANT TO SECTION 13 OR 15(d) OF  
THE SECURITIES EXCHANGE ACT OF 1934

Date of report (date of earliest event reported): December 21, 2006

**ZIOPHARM Oncology, Inc.**

(Exact name of registrant as specified in its charter)

Delaware

0-32353

84-1475642

(State or other jurisdiction of  
incorporation)

(Commission File Number)

(IRS Employer Identification  
No.)

**1180 Avenue of the Americas, 19<sup>th</sup> Floor  
New York, NY 10036**

(Address of principal executive offices) (Zip Code)

**(646) 214-0700**

(Registrant's telephone number, including area code)

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

**Item 1.01. Entry into a Material Definitive Agreement.**

On January 8, 2004, ZIOPHARM Oncology, Inc. (the “Company”) entered into a three year employment agreement with Dr. Jonathan Lewis, pursuant to which Dr. Lewis is serving a Chief Executive Officer of the Company until January 8, 2007. On December 21, 2006, the Company and Dr. Lewis entered into an Employment Agreement Extension (the “Extension”). Pursuant to the Extension, the Company extended the term of Dr. Lewis’ employment to January 8, 2008 and increased Dr. Lewis’ annual base salary to \$385,000.

A copy of the Extension is attached hereto as Exhibit 10.1 and is incorporated herein by reference.

**Item 9.01 Financial Statements and Exhibits.**

(d) Exhibits. The following exhibit is furnished herewith.

<u>Exhibit No.</u>	<u>Description</u>
--------------------	--------------------

10.1	Employment Agreement Extension dated December 21, 2006
------	--

---

**SIGNATURE**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

**ZIOPHARM Oncology, Inc.:**

(Registrant)

Date: December 26, 2006

By: /s/ Richard E. Bagley

---

Richard E. Bagley, President,  
*Chief Operating Officer and Chief Financial Officer*

Exhibit Index

Exhibit No.    Description

10.1            Employment Agreement Extension dated December 21, 2006